share_log

Redhill Biopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

SEC announcement ·  Jan 2 00:00
Summary by Moomoo AI
Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on January 2, 2024, indicating that they no longer beneficially own more than five percent of RedHill Biopharma Ltd.'s ADSs as of December 31, 2023. The filing shows that all three reporting persons have zero shares and zero percent ownership in the class of securities. The entities are associated with each other, with Sabby Management, LLC serving as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz being the manager of Sabby Management, LLC. The filing includes a certification stating that the securities were not acquired for the purpose of changing or influencing the control of RedHill Biopharma and were not held in connection with any transaction having that purpose or effect.
Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on January 2, 2024, indicating that they no longer beneficially own more than five percent of RedHill Biopharma Ltd.'s ADSs as of December 31, 2023. The filing shows that all three reporting persons have zero shares and zero percent ownership in the class of securities. The entities are associated with each other, with Sabby Management, LLC serving as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz being the manager of Sabby Management, LLC. The filing includes a certification stating that the securities were not acquired for the purpose of changing or influencing the control of RedHill Biopharma and were not held in connection with any transaction having that purpose or effect.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more